Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. Br J Haematol 2008 Jun;142(2):318-20
Date
05/22/2008Pubmed ID
18492100DOI
10.1111/j.1365-2141.2008.07184.xScopus ID
2-s2.0-47249105170 (requires institutional sign-in at Scopus site) 7 CitationsAuthor List
Tholouli E, Liakopoulou E, Greenfield HM, Shaw BE, Tauro S, Byrne JL, Dennis M, Burthem J, Lucas GS, Craddock C, Russell NH, Liu Yin JAAuthor
Bronwen E. Shaw MBChB, PhD Center Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Alemtuzumab
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Antineoplastic Agents
Disease-Free Survival
Female
Humans
Leukemia, Myeloid, Acute
Male
Middle Aged
Myelodysplastic Syndromes
Recurrence
Stem Cell Transplantation
Survival Analysis
Young Adult
